Bio-View Ltd (BIOV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bio-View Ltd (BIOV) has a cash flow conversion efficiency ratio of 0.049x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA1.38 Million ≈ $3.70K USD) by net assets (ILA28.28 Million ≈ $75.81K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Bio-View Ltd for the company's overall valuation and market capitalisation.
Bio-View Ltd - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how Bio-View Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bio-View Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bio-View Ltd ranked by their cash flow conversion efficiency. Explore Bio-View Ltd earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Agricore CS Holdings Berhad
KLSE:0309
|
0.138x |
|
MetaLabs Co Ltd
KO:090370
|
0.007x |
|
IWG PLC
LSE:IWG
|
-0.123x |
|
Atossa Genetics Inc
NASDAQ:ATOS
|
-0.121x |
|
Photon Energy N.V.
WAR:PEN
|
0.119x |
|
TMD Energy Limited
NYSE MKT:TMDE
|
N/A |
|
Bannari Amman Spinning Mills Limited
NSE:BASML
|
0.052x |
|
Sidma S.A. Steel Products
AT:SIDMA
|
0.036x |
Annual Cash Flow Conversion Efficiency for Bio-View Ltd (2009–2024)
The table below shows the annual cash flow conversion efficiency of Bio-View Ltd from 2009 to 2024. View Bio-View Ltd (BIOV) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA22.95 Million ≈ $61.52K |
ILA-3.11 Million ≈ $-8.33K |
-0.135x | -2515.71% |
| 2023-12-31 | ILA27.30 Million ≈ $73.20K |
ILA153.00K ≈ $410.19 |
0.006x | -83.63% |
| 2022-12-31 | ILA28.28 Million ≈ $75.81K |
ILA968.00K ≈ $2.60K |
0.034x | -71.36% |
| 2021-12-31 | ILA27.16 Million ≈ $72.82K |
ILA3.25 Million ≈ $8.71K |
0.120x | +273.69% |
| 2020-12-31 | ILA25.07 Million ≈ $67.21K |
ILA802.00K ≈ $2.15K |
0.032x | -68.02% |
| 2019-12-31 | ILA24.95 Million ≈ $66.89K |
ILA2.50 Million ≈ $6.69K |
0.100x | +271.76% |
| 2018-12-31 | ILA22.75 Million ≈ $60.99K |
ILA-1.32 Million ≈ $-3.55K |
-0.058x | -2629.85% |
| 2017-12-31 | ILA23.45 Million ≈ $62.88K |
ILA54.00K ≈ $144.77 |
0.002x | -98.29% |
| 2016-12-31 | ILA27.61 Million ≈ $74.01K |
ILA3.73 Million ≈ $9.99K |
0.135x | -33.43% |
| 2015-12-31 | ILA22.99 Million ≈ $61.63K |
ILA4.66 Million ≈ $12.50K |
0.203x | +12.52% |
| 2014-12-31 | ILA18.18 Million ≈ $48.75K |
ILA3.28 Million ≈ $8.79K |
0.180x | +196.72% |
| 2013-12-31 | ILA15.65 Million ≈ $41.95K |
ILA-2.92 Million ≈ $-7.82K |
-0.186x | -232.37% |
| 2012-12-31 | ILA16.69 Million ≈ $44.76K |
ILA2.35 Million ≈ $6.30K |
0.141x | -34.69% |
| 2011-12-31 | ILA15.20 Million ≈ $40.75K |
ILA3.28 Million ≈ $8.78K |
0.216x | -54.61% |
| 2010-12-31 | ILA8.18 Million ≈ $21.92K |
ILA3.88 Million ≈ $10.41K |
0.475x | +935.47% |
| 2009-12-31 | ILA1.55 Million ≈ $4.15K |
ILA71.00K ≈ $190.35 |
0.046x | -- |
About Bio-View Ltd
Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company's products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatic… Read more